Clinical Trial Update: Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for Pro-ocular 1% assessing safety and efficacy in daily scleral lens wearers with ocular graft-versus-host disease, spanning Phase 2 an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Graft-versus-host Disease

Drugs mentioned

• Pro-ocular 1%

Snippet

Sponsor: Glia, LLC | Conditions: Ocular Graft-versus-host Disease | Phase 2, Phase 3 | Status: UNKNOWN